{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T19:45:42Z","timestamp":1790019942393,"version":"4.0.1"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Cancer J"],"published-print":{"date-parts":[[2023,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Myelodysplastic syndromes (MDSs) are a heterogeneous group of clonal hematopoietic stem cell disorders with treatment approaches tailored to the presence of cytopenias, disease risk, and molecular mutation profile. In higher-risk MDSs, the standard of care are DNA methyltransferase inhibitors, otherwise referred to as hypomethylating agents (HMAs), with consideration for allogeneic hematopoietic stem cell transplantation in appropriate candidates. Given modest complete remission rates (15%\u201320%) with HMA monotherapy and median overall survival of approximately 18 months, there is much interest in the investigation of combination and targeted treatment approaches. Furthermore, there is no standard treatment approach in patients with progression of disease after HMA therapy. In this review, we aim to summarize the current evidence for the B-cell lymphoma-2 inhibitor, venetoclax, and a variety of isocitrate dehydrogenase inhibitors in the treatment of MDSs along with discussing their potential role in the treatment paradigm of this disease.<\/jats:p>","DOI":"10.1097\/ppo.0000000000000657","type":"journal-article","created":{"date-parts":[[2023,5,17]],"date-time":"2023-05-17T14:07:38Z","timestamp":1684332458000},"page":"188-194","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Novel Therapies in Myelodysplastic Syndrome"],"prefix":"10.1097","volume":"29","author":[{"given":"Yasmin","family":"Abaza","sequence":"first","affiliation":[{"name":"Department of Hematology and Oncology, Northwestern University, Robert Lurie Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand Ashwin","family":"Patel","sequence":"additional","affiliation":[{"name":"Section of Hematology\/Oncology, Department of Medicine, University of Chicago, IL."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1056\/NEJMra1904794","article-title":"Myelodysplastic syndromes","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1182\/blood-2012-03-420489","article-title":"Revised international prognostic scoring system for myelodysplastic syndromes","volume":"120","year":"2012","journal-title":"Blood"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","year":"1997","journal-title":"Blood"},{"key":"bib4-20250621","article-title":"Molecular international prognostic scoring system for myelodysplastic syndromes","year":"2022","journal-title":"NEJM Evid"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1182\/asheducation-2013.1.522","article-title":"Who benefits from allogeneic transplantation for myelodysplastic syndromes?: New insights","volume":"2013","year":"2013","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","year":"2009","journal-title":"Lancet Oncol"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1038\/leu.2015.283","article-title":"Comparison of risk stratification tools in predicting outcomes of patients with higher-risk myelodysplastic syndromes treated with azanucleosides","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib8-20250621","article-title":"A systematic review of higher-risk myelodysplastic syndromes clinical trials to determine the benchmark of azacitidine and explore alternative endpoints for overall survival","volume":"104","year":"2021","journal-title":"Leuk Res"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1200\/JCO.2011.35.8135","article-title":"Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure","volume":"29","year":"2011","journal-title":"J Clin Oncol"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1002\/cncr.25247","article-title":"Outcome of patients with myelodysplastic syndrome after failure of decitabine therapy","volume":"116","year":"2010","journal-title":"Cancer"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/j.tcb.2017.06.002","article-title":"Oncogenic activities of IDH1\/2 mutations: from epigenetics to cellular signaling","volume":"27","year":"2017","journal-title":"Trends Cell Biol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ccr.2010.11.015","article-title":"Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation","volume":"18","year":"2010","journal-title":"Cancer Cell"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/leu.2016.275","article-title":"Isocitrate dehydrogenase mutations in myeloid malignancies","volume":"31","year":"2017","journal-title":"Leukemia"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/nm0311-291","article-title":"Metabolism unhinged: IDH mutations in cancer","volume":"17","year":"2011","journal-title":"Nat Med"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/leu.2015.211","article-title":"IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1038\/leu.2015.91","article-title":"Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms","volume":"29","year":"2015","journal-title":"Leukemia"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1200\/JCO.2015.66.2510","article-title":"Randomized phase II study of azacitidine alone or in combination with lenalidomide or with vorinostat in higher-risk myelodysplastic syndromes and chronic myelomonocytic leukemia: North American Intergroup Study SWOG S1117","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1016\/S1470-2045(21)00494-0","article-title":"Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial","volume":"22","year":"2021","journal-title":"Lancet Oncol"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1056\/NEJMoa1716984","article-title":"Durable remissions with Ivosidenib in IDH1-mutated relapsed or refractory AML","volume":"378","year":"2018","journal-title":"N Engl J Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1056\/NEJMoa2117344","article-title":"Ivosidenib and azacitidine in IDH1-mutated acute myeloid leukemia","volume":"386","year":"2022","journal-title":"N Engl J Med"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1182\/blood.2019002140","article-title":"Ivosidenib induces deep durable remissions in patients with newly diagnosed IDH1-mutant acute myeloid leukemia","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1182\/blood-2017-04-779405","article-title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","volume":"130","year":"2017","journal-title":"Blood"},{"issue":"1 Suppl","key":"bib23-20250621","first-page":"62","article-title":"Ivosidenib monotherapy is effective in patients with IDH1 mutated myelodysplastic syndrome (MDS): the Idiome phase 2 study by the GFM group","volume":"138","year":"2021","journal-title":"Blood"},{"issue":"16 Suppl","key":"bib24-20250621","first-page":"7053","article-title":"Ivosidenib in patients with IDH1-mutant relapsed\/refractory myelodysplastic syndrome (R\/R MDS): updated enrollment and results of a phase 1 dose-escalation and expansion substudy","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib25-20250621","first-page":"e46","article-title":"Olutasidenib alone or with azacitidine in IDH1-mutated acute myeloid leukaemia and myelodysplastic syndrome: phase 1 results of a phase 1\/2 trial","volume":"10","year":"2022","journal-title":"Lancet Haematol"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"e309","DOI":"10.1016\/S2352-3026(19)30284-4","article-title":"Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial","volume":"7","year":"2020","journal-title":"Lancet Haematol"},{"issue":"1 Suppl","key":"bib27-20250621","first-page":"63","article-title":"Enasidenib (ENA) is effective in patients with IDH2 mutated myelodysplastic syndrome (MDS): the Ideal Phase 2 Study by the GFM Group","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib28-20250621","article-title":"Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome","year":"2022","journal-title":"Blood Adv"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1182\/blood-2005-10-4149","article-title":"Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia","volume":"108","year":"2006","journal-title":"Blood"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"3091","DOI":"10.1182\/blood.V81.11.3091.3091","article-title":"High expression of BCL-2 protein in acute myeloid leukemia cells is associated with poor response to chemotherapy","volume":"81","year":"1993","journal-title":"Blood"},{"key":"bib31-20250621","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.ccr.2006.10.006","article-title":"Mechanisms of apoptosis sensitivity and resistance to the BH3 mimetic ABT-737 in acute myeloid leukemia","volume":"10","year":"2006","journal-title":"Cancer Cell"},{"key":"bib32-20250621","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.stem.2012.12.013","article-title":"BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells","volume":"12","year":"2013","journal-title":"Cell Stem Cell"},{"key":"bib33-20250621","first-page":"666","article-title":"Overexpression of BCL2 protein predicts chemoresistance in acute myeloid leukemia: its correlation with FLT3","volume":"60","year":"2013","journal-title":"Neoplasma"},{"key":"bib34-20250621","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1158\/2159-8290.CD-16-0313","article-title":"Efficacy and biological correlates of response in a phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia","volume":"6","year":"2016","journal-title":"Cancer Discov"},{"key":"bib35-20250621","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/nm.3048","article-title":"ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets","volume":"19","year":"2013","journal-title":"Nat Med"},{"key":"bib36-20250621","doi-asserted-by":"crossref","first-page":"3371","DOI":"10.1158\/1078-0432.CCR-19-1900","article-title":"5-Azacitidine induces NOXA to prime AML cells for venetoclax-mediated apoptosis","volume":"26","year":"2020","journal-title":"Clin Cancer Res"},{"key":"bib37-20250621","doi-asserted-by":"crossref","first-page":"226","DOI":"10.3109\/10428194.2014.910657","article-title":"Ex vivo activity of BCL-2 family inhibitors ABT-199 and ABT-737 combined with 5-azacytidine in myeloid malignancies","volume":"56","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"bib38-20250621","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","year":"2019","journal-title":"Blood"},{"key":"bib39-20250621","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and venetoclax in previously untreated acute myeloid leukemia","volume":"383","year":"2020","journal-title":"N Engl J Med"},{"key":"bib40-20250621","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/leu.2015.179","article-title":"Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients","volume":"30","year":"2016","journal-title":"Leukemia"},{"key":"bib41-20250621","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1182\/blood.V96.12.3932","article-title":"The role of apoptosis, proliferation, and the BCL-2\u2013related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS","volume":"96","year":"2000","journal-title":"Blood"},{"issue":"Supplement 1","key":"bib42-20250621","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1182\/blood-2021-145613","article-title":"Molecular responses are observed across mutational spectrum in treatment-na\u00efve higher-risk myelodysplastic syndrome patients treated with venetoclax plus azacitidine","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib43-20250621","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/ajh.26771","article-title":"A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes","volume":"98","year":"2023","journal-title":"Am J Hematol"},{"key":"bib44-20250621","doi-asserted-by":"crossref","first-page":"e756","DOI":"10.1016\/S2352-3026(22)00216-2","article-title":"Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1\u20132 study","volume":"9","year":"2022","journal-title":"Lancet Haematol"},{"issue":"1 Suppl","key":"bib45-20250621","first-page":"55","article-title":"Safety, efficacy, and patient-reported outcomes of venetoclax in combination with azacitidine for the treatment of patients with higher-risk myelodysplastic syndrome: a phase 1b study","volume":"136","year":"2020","journal-title":"Blood"},{"issue":"15 Suppl","key":"bib46-20250621","article-title":"Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-na\u00efve higher-risk myelodysplastic syndromes","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"issue":"16 Suppl","key":"bib47-20250621","first-page":"e19068","article-title":"Results of a phase 1 trial of azacitidine with venetoclax in relapsed\/refractory higher-risk myelodysplastic syndrome (MDS)","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"key":"bib48-20250621","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1038\/leu.2014.44","article-title":"BCL-2 family proteins as 5-azacytidine\u2013sensitizing targets and determinants of response in myeloid malignancies","volume":"28","year":"2014","journal-title":"Leukemia"},{"key":"bib49-20250621","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1182\/bloodadvances.2020001482","article-title":"Venetoclax and hypomethylating agents (HMAs) induce high response rates in MDS, including patients after HMA therapy failure","volume":"4","year":"2020","journal-title":"Blood Adv"},{"key":"bib50-20250621","first-page":"E214","article-title":"Real-world experience with venetoclax and hypomethylating agents in myelodysplastic syndromes with excess blasts","volume":"97","year":"2022","journal-title":"Am J Hematol"},{"key":"bib51-20250621","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s41408-022-00744-z","article-title":"Assessing the role of venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndrome","volume":"12","year":"2022","journal-title":"Blood Cancer J"},{"key":"bib52-20250621","doi-asserted-by":"crossref","first-page":"2700","DOI":"10.1080\/10428194.2020.1775214","article-title":"Venetoclax and hypomethylating agent therapy in high risk myelodysplastic syndromes: a retrospective evaluation of a real-world experience","volume":"61","year":"2020","journal-title":"Leuk Lymphoma"},{"key":"bib53-20250621","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1182\/blood.2019004143","article-title":"Oral cedazuridine\/decitabine for MDS and CMML: a phase 2 pharmacokinetic\/pharmacodynamic randomized crossover study","volume":"136","year":"2020","journal-title":"Blood"},{"key":"bib54-20250621","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nm.3788","article-title":"Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia","volume":"21","year":"2015","journal-title":"Nat Med"},{"key":"bib55-20250621","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1182\/blood.2019003988","article-title":"Molecular patterns of response and treatment failure after frontline venetoclax combinations in older patients with AML","volume":"135","year":"2020","journal-title":"Blood"},{"key":"bib56-20250621","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1038\/s41375-021-01468-y","article-title":"Enasidenib-induced differentiation promotes sensitivity to venetoclax in IDH2-mutated acute myeloid leukemia","volume":"36","year":"2022","journal-title":"Leukemia"},{"issue":"1 Suppl","key":"bib57-20250621","first-page":"1263","article-title":"Enasidenib in combination with venetoclax in IDH2-mutated myeloid malignancies: preliminary results of the phase Ib\/II Enaven-AML Trial","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib58-20250621","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1038\/s41408-021-00604-2","article-title":"Efficacy and safety of enasidenib and azacitidine combination in patients with IDH2 mutated acute myeloid leukemia and not eligible for intensive chemotherapy","volume":"12","year":"2022","journal-title":"Blood Cancer J"},{"key":"bib59-20250621","first-page":"E154","article-title":"Decitabine and venetoclax for IDH1\/2-mutated acute myeloid leukemia","volume":"96","year":"2021","journal-title":"Am J Hematol"},{"issue":"15 Suppl","key":"bib60-20250621","first-page":"7012","article-title":"A phase Ib\/II study of ivosidenib with venetoclax +\/\u2212 azacitidine in IDH1-mutated myeloid malignancies","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"key":"bib61-20250621","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1182\/blood-2014-10-604975","article-title":"Inhibition of Mcl-1 with the pan-BCL-2 family inhibitor (\u2212)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia","volume":"126","year":"2015","journal-title":"Blood"},{"key":"bib62-20250621","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1158\/2159-8290.CD-18-0387","article-title":"AMG 176, a selective MCL1 inhibitor, is effective in hematologic cancer models alone and in combination with established therapies","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"bib63-20250621","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1038\/s41375-018-0261-3","article-title":"Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia","volume":"33","year":"2019","journal-title":"Leukemia"},{"key":"bib64-20250621","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1158\/2159-8290.CD-18-0140","article-title":"A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous leukemia","volume":"8","year":"2018","journal-title":"Cancer Discov"},{"key":"bib65-20250621","doi-asserted-by":"crossref","first-page":"107206","DOI":"10.18632\/oncotarget.22284","article-title":"Combined venetoclax and alvocidib in acute myeloid leukemia","volume":"8","year":"2017","journal-title":"Oncotarget"},{"key":"bib66-20250621","article-title":"Venetoclax and idasanutlin in relapsed\/refractory AML: a non-randomized, open-label phase 1b trial","year":"2022","journal-title":"Blood"},{"key":"bib67-20250621","doi-asserted-by":"crossref","first-page":"697","DOI":"10.3324\/haematol.2018.205534","article-title":"Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models","volume":"105","year":"2020","journal-title":"Haematologica"},{"issue":"1 Suppl","key":"bib68-20250621","first-page":"510","article-title":"Combined blockade of CD47-Sirpa interaction by 5F9 (magrolimab) and azacitidine\/venetoclax therapy facilitates macrophage-mediated anti-leukemia efficacy in AML pre-clinical models","volume":"138","year":"2021","journal-title":"Blood"},{"key":"bib69-20250621","doi-asserted-by":"crossref","first-page":"4048","DOI":"10.1200\/JCO.22.00602","article-title":"Venetoclax plus gilteritinib for FLT3-mutated relapsed\/refractory acute myeloid leukemia","volume":"40","year":"2022","journal-title":"J Clin Oncol"},{"issue":"1 Suppl","key":"bib70-20250621","first-page":"9057","article-title":"Umbrella trial in myeloid malignancies: the Myelomatch National Clinical Trials Network Precision Medicine Initiative","volume":"140","year":"2022","journal-title":"Blood"}],"container-title":["The Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000657","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T17:04:00Z","timestamp":1750525440000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/PPO.0000000000000657"}},"subtitle":["Where Do Venetoclax and Isocitrate Dehydrogenase Inhibitors Fit in?"],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":70,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/ppo.0000000000000657","relation":{},"ISSN":["1540-336X","1528-9117"],"issn-type":[{"value":"1540-336X","type":"electronic"},{"value":"1528-9117","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]}}}